This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CPRX

Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis

Catalyst Pharmaceuticals logo

About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX)

Key Stats

Today's Range
$31.49
▼
$31.49
50-Day Range
$31.34
▼
$31.51
52-Week Range
$19.05
▼
$32.56
Volume
N/A
Average Volume
2.62 million shs
Market Capitalization
$3.86 billion
P/E Ratio
18.10
Dividend Yield
N/A
Price Target
$31.67
Consensus Rating
Moderate Buy

Company Overview

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS). In addition, Catalyst markets Ruzurgi® (amifampridine) tablets for pediatric LEMS patients. Beyond these approved therapies, Catalyst is advancing its pipeline programs that aim to extend its expertise in ion channel modulators to other rare and difficult-to-treat conditions.

Founded in 2002 and headquartered in Coral Gables, Florida, Catalyst Pharmaceuticals went public on the Nasdaq Stock Market. The company focuses its operations on clinical development, regulatory strategy and commercialization activities within the United States. Catalyst continues to explore opportunities for international collaborations and licensing arrangements to broaden patient access to its rare disease portfolio.

Catalyst is led by President and Chief Executive Officer Patrick J. McEnany, who brings extensive experience in pharmaceutical product development and commercialization. Under his leadership, the company has strengthened its regulatory and commercial capabilities while advancing its pipeline toward future regulatory filings and potential approvals.

AI Generated. May Contain Errors.

Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CPRX Stock News Headlines

$0. Later: $29.97.
Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.tc pixel
See More Headlines

CPRX Stock Analysis - Frequently Asked Questions

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released its earnings results on Thursday, November, 6th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.50 by $0.18. The biopharmaceutical company had revenue of $148.39 million for the quarter, compared to analyst estimates of $136.79 million. Catalyst Pharmaceuticals had a net margin of 37.08% and a trailing twelve-month return on equity of 35.76%.
Read the conference call transcript
.

Catalyst Pharmaceuticals' Board of Directors authorized a stock repurchase program on Wednesday, October 1st 2025, which allows the company to repurchase $200 million in outstanding shares, according to EventVestor. This means that the company could repurchase up to 8.3% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's leadership believes its stock is undervalued.

Catalyst Pharmaceuticals' top institutional shareholders include IFP Advisors Inc. Insiders that own company stock include Steve Miller, David S Tierney, Brian Elsbernd, Richard J Daly, Gary Ingenito, Alicia Grande, Preethi Sundaram, Carmen Jeffrey Del and Molly Harper.
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Catalyst Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU), Plug Power (PLUG), Viking Therapeutics (VKTX) and Palantir Technologies (PLTR).

Company Calendar

Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:CPRX
CIK
1369568
Employees
80
Year Founded
2002

Price Target and Rating

High Price Target
$32.00
Low Price Target
$31.50
Potential Upside/Downside
+0.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.74
Trailing P/E Ratio
18.10
Forward P/E Ratio
10.22
P/E Growth
0.96
Net Income
$214.33 million
Net Margins
37.08%
Pretax Margin
49.66%
Return on Equity
35.76%
Return on Assets
31.31%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.10
Quick Ratio
6.84

Sales & Book Value

Annual Sales
$596.96 million
Price / Sales
6.46
Cash Flow
$2.92 per share
Price / Cash Flow
10.77
Book Value
$7.76 per share
Price / Book
4.06

Miscellaneous

Outstanding Shares
122,420,000
Free Float
109,688,000
Market Cap
$3.86 billion
Optionable
Optionable
Beta
0.74

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

This page (NASDAQ:CPRX) was last updated on 7/16/2026 by MarketBeat.com Staff.
From Our Partners